Neurotech International Limited (ASX:NTI) is a clinical-stage biopharmaceutical development company focused predominantly on paediatric neurological disorders, where there is persistent neuroinflammation. Neurotech has completed a Phase I/II clinical trial in Autism Spectrum Disorder (ASD), which demonstrated excellent safety and efficacy results at 28 days, 20 weeks and 52 weeks of treatment with NTI164. The Company commenced Phase II/III randomised, double-blind, placebo controlled clinical trial in ASD in Q4 CY2022. Neurotech is also conducting additional Phase I/II trials in Paediatric Autoimmune Neuropsychiatric Disorders Associated with Streptococcal Infections (PANDAS) and Paediatric Acute-Onset Neuropsychiatric Syndrome (PANS), collectively PANDAS/PANS, along with Rett Syndrome and Cerebral Palsy during CY2023.
NTI164 is a proprietary drug formulation derived from a unique cannabis strain with low THC (M<0.3%) and a novel combination of cannabinoids including CBDA, CBC, CBDP, CBDB and CBN.
NTI164 has been exclusively licenced for neurological applications globally. Pre-clinical studies have demonstrated a potent anti-proliferative, anti-oxidative, anti-inflammatory and neuro-protective effects in human neuronal and microglial cells. NTI164 is being developed as a therapeutic drug product for a range of neurological disorders in children where neuroinflammation is involved.

KEY PEOPLE

  • Dr Thomas Duthy, Executive Director

    Dr Duthy has over 19 years of direct financial markets experience having worked in sell-side
    equity research, and senior executive roles across investor relations and corporate
    development, along with a number of Executive and Non-Executive ASX Board appointments.
    Dr Duthy is the Founder and CEO of Nemean Group Pty Ltd, a boutique corporate advisory
    and investor relations firm specialising in delivering value-added services across the life
    sciences, medical devices, healthcare, technology and emerging company sectors.
    Transactions have included the A$100 million cash sale of the Ellex Medical (ASX:EYE)
    ophthalmic laser business to Lumibird in 2020 and the A$111 million cash acquisition of
    Limeade (ASX:LME) by WebMD Health Services in 2023. Prior to establishing Nemean Group
    in October 2018, Dr Duthy was the Global Head of Investor Relations &amp; Corporate
    Development at Sirtex Medical Limited (ASX:SRX), which was sold to CDH Investments in
    September 2018 for A$1.9 billion.

    read more

  • Mr Gerald Quigley, Director of Public Relations

    Pharmacist and consumer health commentator. Leading media health commentator heard each week on television and radio stations across Australia. Extensive knowledge relating to pharmaceutical/ nutraceutical product development, dispensing &amp; marketing in addition to
    product positioning within the relevant regulatory landscapes (eg. TGA, FDA).

    read more

RELATED STOCKHEAD STORIES